Peptide

GHRP-2

Also known as

Pralmorelin · Pralmorelin hydrochloride · KP-102 · KP-102LN · GPA 748 · GPA-748 · WAY-GPA-748 · GHRP Kaken 100 · Growth hormone-releasing peptide-2 · GHRP2 · GHRP 2 · D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys-NH2

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Identity	Pralmorelin, a peptide that encourages pituitary growth-hormone release through ghrelin signaling. People discuss it for appetite, sleep and training recovery.
Forms	Community reports center on injections beneath the skin, with some nasal accounts. It is different from injected HGH and GHRH peptides such as sermorelin.

Notes

GHRP-2, also called pralmorelin, is a peptide discussed for growth-hormone pulses, appetite, sleep and recovery. Community interest centers on a hunger wave and possible training benefits, with accounts also describing little change, poor sleep or fluid retention. A stronger sensation does not prove a stronger result.

Pralmorelin is a growth-hormone-releasing peptide. It imitates part of ghrelin's signaling, encouraging the pituitary to release GH. It is not injected HGH, a steroid, or a GHRH peptide such as sermorelin. Hunger and a measured GH rise are separate effects. Laferrère et al. 2005: GHRP-2 increases food intake in healthy men (Official context · Accessed 2026-09-30)

Community use centers on injections beneath the skin. SubQ reports dominate the preserved record; nasal accounts also exist. Intramuscular reports are less prominent, while IV tests and oral-development mentions are different contexts—not equivalent forms with interchangeable amounts. Sleep Problems on GHRP-2+mod grf (Personal report · Accessed 2026-09-30)

Source context — Laferrère et al. 2005: GHRP-2 increases food intake in healthy men: Primary abstract inspected by API; PubMed access became intermittent and PMC challenged. Infusion experiment differs from community bolus injections; not bodybuilding effectiveness evidence.

Source context — Sleep Problems on GHRP-2+mod grf: One injected-stack insomnia account and a different nasal-use account. Reply's cortisol explanation is speculation, without labs. Dose comment omits units; do not silently supply them.

What people notice

Hunger	A short hunger wave can help eating during a bulk and undermine a cut. Some blend accounts instead report appetite loss; hunger does not verify product activity.
Sleep and recovery	One nasal user reported better sleep and slightly better recovery. Other users describe insomnia, little early benefit or fluid retention.
Physique reports	An early stacked log mentioned strength changes and bloat, with groin pain and visible fat loss unchanged at day 19. Fullness is not proof of muscle gain.

Notes

Appetite can help a bulk and complicate a cut. Two opened discussions describe a hunger wave fading around twenty minutes. People seeking easier eating may welcome that; appetite-loss reports also occur in blends, so hunger is not a dependable response or product test. Finally Not the Skinny Guy Anymore — Peptide Journey (Personal report · Accessed 2026-09-30) · Documenting experience with GHRP-2 and CJC-1295 (Mod GRF 1-29) (Personal report · Accessed 2026-09-30) · Ipa/cjc/ghrp-2 blend - normal side-effects? (Personal report · Accessed 2026-09-30)

Sleep, recovery and physique changes are mixed. A nasal user described better sleep and slightly better gym recovery. Other users reported insomnia or no early benefit. Older logs discuss soreness, fullness, skin and strength, usually alongside GHRH, training and calorie changes. Sleep Problems on GHRP-2+mod grf (Personal report · Accessed 2026-09-30) · Documenting experience with GHRP-2 and CJC-1295 (Mod GRF 1-29) (Personal report · Accessed 2026-09-30)

An early improvement can remain an incomplete result. A 2014 stacked log mentions less joint discomfort, bloat and strength changes, yet groin pain and visible fat loss were unchanged at day 19. Early sensations and scale increases did not establish repair or muscle gain. My GHRP2/Mod GRF 1-29 Log (Personal report · Accessed 2026-09-30)

Source context — Finally Not the Skinny Guy Anymore — Peptide Journey: OP uses GHRP-6, a different compound and person. Only explicitly identified GHRP-2 replies support this card; no dose given.

Source context — Documenting experience with GHRP-2 and CJC-1295 (Mod GRF 1-29): Stacked, subjective accounts and incomplete laboratory follow-up. No-cycle opinion and potency comparisons are not safety findings. TB-500/stretching shoulder outcome is not GHRP-2 monotherapy evidence.

Source context — Ipa/cjc/ghrp-2 blend - normal side-effects?: Unverified equal-mass three-peptide blend. Self-calculated nominal component amounts; no independent content verification. Appetite loss and libido loss cannot be assigned to GHRP-2 alone.

Source context — My GHRP2/Mod GRF 1-29 Log: Recent steroid cycle/PCT, changing calories, GHRH partner and other drugs confound improvement and bloat. Page also contains unsafe advice; no adoption of self-treatment, purity inference or wound claims.

Doses people talk about

Subcutaneous chart band	100–300 mcg per administration, one to three times daily. Separate patterns include 100–200 mcg bedtime-only or 150–200 mcg twice daily; amounts are per injection.
Reviewed dual-peptide log	100 mcg GHRP-2 plus 100 mcg CJC no-DAC twice daily: 200 mcg/day of each peptide, rather than 200 mcg/day of the whole mixture.
High outlier	One user reported 500 mcg per injection three times daily, or 1,500 mcg/day. Stronger sensations did not measure GH or establish safety.
Triple blend	One account calculated 50 mcg each of ipamorelin, CJC no-DAC and GHRP-2 per dose, two or three times daily. The 150 mcg total is not all GHRP-2.

Notes

SubQ charts describe 100–300 mcg per administration, one to three times daily. The preserved record separates 100–200 mcg bedtime-only, 150–200 mcg twice daily, and 200–300 mcg two or three times daily. Its 200–900 mcg/day summary is not exhaustive: 100 mcg once daily is a separate pattern. mcg means micrograms.

One reviewed log reports 100 mcg of each peptide twice daily. That is 200 mcg/day of GHRP-2 plus 200 mcg/day of CJC no-DAC, not 200 mcg of the combined mixture. Preserved partner charts discuss 100–200 mcg of each component; the partner amount does not double GHRP-2. Documenting experience with GHRP-2 and CJC-1295 (Mod GRF 1-29) (Personal report · Accessed 2026-09-30)

Higher outliers are separate from the chart band. One Reddit user reports 500 mcg per injection three times daily—1,500 mcg/day—and stronger sensations after hunger faded. Preserved 1–2 mcg/kg 'saturation' lore is clinical extrapolation, not a proven SubQ ceiling; subjective intensity does not measure GH or establish safety. How much ghrp2 can you take a day? (Personal report · Accessed 2026-09-30)

A 3/3/3 mg blend is an equal-mass three-component vial. One poster described nominal 50 mcg each of ipamorelin, CJC no-DAC and GHRP-2 per dose: 150 mcg combined, two or three times daily. Label and self-calculation do not verify delivered content; this differs from 150 mcg of GHRP-2 alone. Ipa/cjc/ghrp-2 blend - normal side-effects? (Personal report · Accessed 2026-09-30)

Source context — How much ghrp2 can you take a day?: 500 mcg three-times-daily report is an outlier. Felt GH pulse is subjective; no assays or safety follow-up. Explicit micrograms, injection slang; route unspecified.

Half-life, onset & duration

Felt onset	Saved reports place acute sensations within 15–60 minutes and strongest hunger around 20–30 minutes.
Felt duration	Two individuals describe about twenty minutes of hunger. The circulated two-to-three-hour GH pulse is a different, unmeasured endpoint in those discussions.
Half-life	Forum estimates include 30 or 30–60 minutes without establishing adult subcutaneous clearance. A ten-child IV study measured about 33 minutes; route and population differ.

Notes

Hunger may arrive quickly, but early response varies. Preserved reports place acute sensations within 15–60 minutes and strongest hunger around 20–30 minutes. Other inspected accounts describe immediate mild hunger or little change. Neither an early sensation nor its absence verifies GH release. Documenting experience with GHRP-2 and CJC-1295 (Mod GRF 1-29) (Personal report · Accessed 2026-09-30)

About twenty minutes of hunger in two individual accounts. Unhappy-Product-1526 and BioBuild describe this short window; it is not a universal duration. Another poster says hunger faded after several weeks of use. Single-dose sensation and adaptation across a course are different clocks. Finally Not the Skinny Guy Anymore — Peptide Journey (Personal report · Accessed 2026-09-30) · Documenting experience with GHRP-2 and CJC-1295 (Mod GRF 1-29) (Personal report · Accessed 2026-09-30) · How much ghrp2 can you take a day? (Personal report · Accessed 2026-09-30)

A two-to-three-hour GH pulse is circulated stack lore. The opened triple-blend discussion repeats this estimate rather than measuring it. It does not establish hours of felt recovery, all-day GH elevation or how long physique changes persist after stopping. Some Qs about end of winter plan (Secondhand community claim · Accessed 2026-09-30)

Forum estimates include 30 minutes and 30–60 minutes. The Reddit estimate is repeated reading; Eroids frames 30–60 minutes as a question. Preserved guides also quote 15–30, 25–40 labeled IV, and a broader 15–60 minutes. Their underlying origins are uneven; none establishes a general adult SubQ half-life. Some Qs about end of winter plan (Secondhand community claim · Accessed 2026-09-30) · GHRP-2 (Secondhand community claim · Accessed 2026-09-30)

About 33 minutes was measured in children after an IV dose. Pihoker's ten-child study used 1 mcg/kg IV and found mean parent-peptide terminal half-life 0.55±0.14 hours. Released GH peaked around 25 minutes and had separate kinetics. These measurements do not become adult SubQ community clocks. Pihoker et al. 1998: GHRP-2 pharmacokinetics in children (Official context · Accessed 2026-09-30)

Source context — Some Qs about end of winter plan: Proposed triple blend, not completed results. Thirty-minute half-life and two-to-three-hour combined pulse are repeated lore without a cited measurement. Blend component amounts unclear; not used as dosage evidence.

Source context — GHRP-2: Thirty-to-sixty-minute figure is something OP found elsewhere, not measured. Commercial source-review forum, but no seller recommendation adopted.

Source context — Pihoker et al. 1998: GHRP-2 pharmacokinetics in children: Primary abstract fetched with Python urllib after PubMed/publisher failed. No full-text inspection. Clearance is pediatric IV, not adult SubQ; GH and parent peptide have different kinetics.

Cycles people discuss

Course lengths	Saved patterns include 4–6-week probes, 8–12 weeks or 8–16 weeks. One nasal account lasted about two months; these accounts do not establish an optimal course length.
Breaks	Four to eight weeks off, eight on/eight off and five days on/two off all appear, alongside daily-use and no-cycle opinions. Sensitivity-reset explanations remain unproven.

Notes

Preserved courses range from 4–6-week probes to 8–12 or 8–16 weeks. The shorter blocks assess tolerance and perceived response; longer blocks concern physique goals. A nasal user reports about two months. No opened comparison establishes an effective or safe course length. Sleep Problems on GHRP-2+mod grf (Personal report · Accessed 2026-09-30)

Breaks include 4–8 weeks off, 8 on/8 off, and 5 days on/2 off. Other discussions describe daily use or argue no cycling is needed. Cost, sensitivity and hormone-normalization explanations remain lore. The original record describes no loading phase and open-ended longevity use without dependable long-term evidence. Documenting experience with GHRP-2 and CJC-1295 (Mod GRF 1-29) (Personal report · Accessed 2026-09-30) · Ipa/cjc/ghrp-2 blend - normal side-effects? (Personal report · Accessed 2026-09-30)

Stacks

GHRH partners	Mod GRF/CJC no-DAC and sermorelin recur. CJC with DAC also appears; the longer-acting partner does not make GHRP-2 long-acting.
Other GH-axis drugs	GHRP-6 or ipamorelin combinations appear, although some call a second GHRP redundant. MK-677 or HGH co-use makes individual effects harder to separate.
Recovery combinations	BPC-157 and TB-500 occur alongside it for soft-tissue goals, without demonstrated GHRP-2 combination benefit.

Notes

GHRH partners and two-GHRP blends raise different questions. Mod GRF/no-DAC or sermorelin pairings recur; DAC changes the partner's exposure, not GHRP-2's identity. Some replies call a second GHRP redundant, while others propose it. MK-677, HGH or BPC/TB-500 co-use further obscures credit. Documenting experience with GHRP-2 and CJC-1295 (Mod GRF 1-29) (Personal report · Accessed 2026-09-30) · Some Qs about end of winter plan (Secondhand community claim · Accessed 2026-09-30)

Classic dual pulse: GHRP-2 + CJC-1295 no-DAC / Mod GRF 1-29 — default synergistic GHRH + GHRP stack; often ~100–200 mcg each same syringe. [community]

Sermorelin partner: GHRP-2 + sermorelin as alternate shorter GHRH path in clinic/forum talk. [community]

CJC with DAC + GHRP-2: Still appears for convenience / IGF-1 elevation lore; pulse purists often prefer no-DAC + multi-daily GHRP-2. [community]

Historical GHRP mixes: Older GHRP-2 + GHRP-6 blends; modern logs usually pick one GHRP and one GHRH instead of two GHRPs. [community]

Recovery adjacency: Sometimes next to BPC-157 / TB-500 for soft-tissue goals — confounded, not proven GHRP-2 synergy. [community]

Watch for

Appetite, fluid and sleep	Reports include overeating, poor sleep, puffiness, tight rings, tingling, headaches, dizziness and injection-site irritation. Symptoms do not prove potency.
Other hormones	Human IV experiments also raised prolactin, ACTH and cortisol. Forum explanations for an individual's libido or sleep problem are guesses without measurements.
Serious-event context	FDA material flags risks from impurities and immune reactions. Serious events occurred in critically ill people, without establishing that GHRP-2 caused them. It does not give event rates for healthy gym users.
Tested sport	The saved WADA S2 record explicitly names GHRP-2/pralmorelin as prohibited at all times. Short half-life claims do not establish a detection window.

Notes

Hunger, poor sleep, fluid retention and tingling can matter. The preserved record adds puffiness, tight rings, headaches, fatigue, injection-site irritation, flushing, dizziness and drowsiness. Libido or mood changes also appear. Cancer-history cautions concern GH/IGF signaling, without establishing a GHRP-2-specific cancer risk. Symptoms do not prove potency. Ipa/cjc/ghrp-2 blend - normal side-effects? (Personal report · Accessed 2026-09-30) · How much ghrp2 can you take a day? (Personal report · Accessed 2026-09-30)

Hunger / overeating: Strongest consistent practical effect (trial food-intake increases and community logs); main cut/recomp downside even though milder than GHRP-6 for many. [trial]

GHRP-2 is not specific to GH alone. Human IV experiments also found prolactin, ACTH and cortisol increases. Forum claims that these hormones caused a particular person's insomnia or libido problem remain guesses without measurements. Arvat et al. 1997: GH, prolactin, ACTH and cortisol responses (Official context · Accessed 2026-09-30) · Sleep Problems on GHRP-2+mod grf (Personal report · Accessed 2026-09-30)

FDA flags injectable and nasal compounding risks. Its page identifies impurities, aggregation and immune-reaction concerns, plus increased insulin requirements, infection, pancreatitis and deaths in critically ill subjects. Causality was not established; this does not mean such outcomes were proved in healthy gym users. FDA: Certain bulk drug substances that may present significant safety risks (Official context · Accessed 2026-09-30)

Tested sport: prohibited at all times under WADA S2. GHRP-2/pralmorelin is named explicitly. Short half-life lore is not a dependable anti-doping clearance window. WADA: The Prohibited List (Official context · Accessed 2026-09-30)

Source context — Arvat et al. 1997: GH, prolactin, ACTH and cortisol responses: Primary abstract only via API; returned text has malformed/truncated phrases. Only clearly legible finding of GH and other-hormone increases adopted. No universal saturation threshold inferred.

Source context — FDA: Certain bulk drug substances that may present significant safety risks: Causality of listed serious events is unestablished. Critically ill deaths must not become a claim of deaths in healthy bodybuilding users. This page does not resolve every current compounding eligibility question.

Source context — WADA: The Prohibited List: Anti-doping context, not legal classification, purchase permission or a detection-window calculation.

Full notes

What GHRP-2 is

Pralmorelin is a growth-hormone-releasing peptide. It imitates part of ghrelin's signaling, encouraging the pituitary to release GH. It is not injected HGH, a steroid, or a GHRH peptide such as sermorelin. Hunger and a measured GH rise are separate effects. Official context Community
Community use centers on injections beneath the skin. SubQ reports dominate the preserved record; nasal accounts also exist. Intramuscular reports are less prominent, while IV tests and oral-development mentions are different contexts—not equivalent forms with interchangeable amounts. Community Personal report

Why people look it up

Appetite can help a bulk and complicate a cut. Two opened discussions describe a hunger wave fading around twenty minutes. People seeking easier eating may welcome that; appetite-loss reports also occur in blends, so hunger is not a dependable response or product test. Personal report Personal report Personal report
Sleep, recovery and physique changes are mixed. A nasal user described better sleep and slightly better gym recovery. Other users reported insomnia or no early benefit. Older logs discuss soreness, fullness, skin and strength, usually alongside GHRH, training and calorie changes. Personal report Personal report Community

Doses people discuss

Reported amounts and schedules explain discussion; they are not instructions.

SubQ charts describe 100–300 mcg per administration, one to three times daily. The preserved record separates 100–200 mcg bedtime-only, 150–200 mcg twice daily, and 200–300 mcg two or three times daily. Its 200–900 mcg/day summary is not exhaustive: 100 mcg once daily is a separate pattern. mcg means micrograms. Community
One reviewed log reports 100 mcg of each peptide twice daily. That is 200 mcg/day of GHRP-2 plus 200 mcg/day of CJC no-DAC, not 200 mcg of the combined mixture. Preserved partner charts discuss 100–200 mcg of each component; the partner amount does not double GHRP-2. Personal report Community
Higher outliers are separate from the chart band. One Reddit user reports 500 mcg per injection three times daily—1,500 mcg/day—and stronger sensations after hunger faded. Preserved 1–2 mcg/kg 'saturation' lore is clinical extrapolation, not a proven SubQ ceiling; subjective intensity does not measure GH or establish safety. Personal report Community
A 3/3/3 mg blend is an equal-mass three-component vial. One poster described nominal 50 mcg each of ipamorelin, CJC no-DAC and GHRP-2 per dose: 150 mcg combined, two or three times daily. Label and self-calculation do not verify delivered content; this differs from 150 mcg of GHRP-2 alone. Personal report

Half-life

Forum estimates include 30 minutes and 30–60 minutes. The Reddit estimate is repeated reading; Eroids frames 30–60 minutes as a question. Preserved guides also quote 15–30, 25–40 labeled IV, and a broader 15–60 minutes. Their underlying origins are uneven; none establishes a general adult SubQ half-life. Reddit r/Peptides Eroids Community

Onset: when people notice something

Hunger may arrive quickly, but early response varies. Preserved reports place acute sensations within 15–60 minutes and strongest hunger around 20–30 minutes. Other inspected accounts describe immediate mild hunger or little change. Neither an early sensation nor its absence verifies GH release. Community Personal report
Sleep and physique reports concern repeated use. The original record describes first-week sleep/appetite, weeks 1–2 fullness or recovery ease, and weeks 6–8 or 10–16 physique claims. These are attributed checkpoints, not a reliable timetable; opened accounts include unchanged or disrupted sleep. Community Personal report

Duration: how long a change lasts

About twenty minutes of hunger in two individual accounts. Unhappy-Product-1526 and BioBuild describe this short window; it is not a universal duration. Another poster says hunger faded after several weeks of use. Single-dose sensation and adaptation across a course are different clocks. Personal report Personal report Personal report
A two-to-three-hour GH pulse is circulated stack lore. The opened triple-blend discussion repeats this estimate rather than measuring it. It does not establish hours of felt recovery, all-day GH elevation or how long physique changes persist after stopping. Reddit r/Peptides

Cycles and breaks

Preserved courses range from 4–6-week probes to 8–12 or 8–16 weeks. The shorter blocks assess tolerance and perceived response; longer blocks concern physique goals. A nasal user reports about two months. No opened comparison establishes an effective or safe course length. Community Personal report
Breaks include 4–8 weeks off, 8 on/8 off, and 5 days on/2 off. Other discussions describe daily use or argue no cycling is needed. Cost, sensitivity and hormone-normalization explanations remain lore. The original record describes no loading phase and open-ended longevity use without dependable long-term evidence. Community Personal report Personal report

Good to know

Hunger, poor sleep, fluid retention and tingling can matter. The preserved record adds puffiness, tight rings, headaches, fatigue, injection-site irritation, flushing, dizziness and drowsiness. Libido or mood changes also appear. Cancer-history cautions concern GH/IGF signaling, without establishing a GHRP-2-specific cancer risk. Symptoms do not prove potency. Community Personal report Personal report
GHRP-2 is not specific to GH alone. Human IV experiments also found prolactin, ACTH and cortisol increases. Forum claims that these hormones caused a particular person's insomnia or libido problem remain guesses without measurements. Official context Personal report
FDA flags injectable and nasal compounding risks. Its page identifies impurities, aggregation and immune-reaction concerns, plus increased insulin requirements, infection, pancreatitis and deaths in critically ill subjects. Causality was not established; this does not mean such outcomes were proved in healthy gym users. Official context
Tested sport: prohibited at all times under WADA S2. GHRP-2/pralmorelin is named explicitly. Short half-life lore is not a dependable anti-doping clearance window. Official context

What community experience adds

Eating windows can collide with the hunger window. Charts discuss about 2 hours after food and 20–30 to 30–60 minutes before eating, with pulses often 3 hours apart. Forum replies disagree. These fasting rituals and insulin explanations do not establish one mandatory window. Community
A stronger-feeling option is not automatically a better result. Comparison talk ranks GHRP-2 as more forceful than ipamorelin and less hungry than GHRP-6; hexarelin is discussed as more troublesome. A user preferring GHRP-2 for appetite and others choosing ipamorelin reflect different priorities, not established superiority. Personal report Community Community
GHRH partners and two-GHRP blends raise different questions. Mod GRF/no-DAC or sermorelin pairings recur; DAC changes the partner's exposure, not GHRP-2's identity. Some replies call a second GHRP redundant, while others propose it. MK-677, HGH or BPC/TB-500 co-use further obscures credit. Personal report Reddit r/Peptides Community
An early improvement can remain an incomplete result. A 2014 stacked log mentions less joint discomfort, bloat and strength changes, yet groin pain and visible fat loss were unchanged at day 19. Early sensations and scale increases did not establish repair or muscle gain. Personal report
Labs and absent effects leave room for uncertainty. Discussion includes IGF-1, glucose, prolactin and cortisol checks. Users speculate about timing, products or a missing partner after roughly 4 weeks without change; those explanations do not diagnose the cause or justify escalation. A random GH result cannot describe the whole pulse. Community Community

What the human studies actually measured

About 33 minutes was measured in children after an IV dose. Pihoker's ten-child study used 1 mcg/kg IV and found mean parent-peptide terminal half-life 0.55±0.14 hours. Released GH peaked around 25 minutes and had separate kinetics. These measurements do not become adult SubQ community clocks. Official context
An appetite experiment used an infusion, not a gym injection schedule. Seven lean men received 1 mcg/kg/hour SubQ for 270 minutes and ate about 36% more than with saline. That supports an acute appetite effect in this experiment, not long-term muscle, fat-loss, sleep or anti-aging promises. Official context